If you want to take card payments for research peptides, a mainstream aggregator is not a real option. Stripe, PayPal, Square and Shopify Payments all classify the category as restricted or prohibited. They may let you sign up — onboarding is automated — but that is not underwriting, and the review comes later.
A high-risk merchant account is the alternative: an account underwritten on purpose, by a processor working with a sponsor bank that is comfortable with the category. It costs more, requires real documentation, and comes with a reserve. In exchange, you get an approval that holds.
- A high-risk merchant account is a real approval, not a delay. The higher rate is the price of stability.
- Disclose the category accurately. Softening it on the application is a misrepresentation to a financial institution — it's what converts an account closure into a 180-day fund hold.
- Underwriters read your website before they read your paperwork. Compliance drift on product pages declines applications.
- Expect a reserve. Negotiate the cap and the release schedule, not the existence of it.
- Applications stall on missing documents, not on the category. Assemble everything before you apply.
What "high-risk" actually means
High-risk isn't a judgement about your ethics. It's a classification about chargeback and regulatory exposure from the acquiring bank's point of view. Categories land there for a mix of reasons: elevated dispute rates, regulatory ambiguity, cross-border shipping, high average order values, or reputational sensitivity for the bank.
Research peptides tick several of those boxes at once. The result is that the automated, self-serve payment layer most ecommerce founders take for granted is closed to you — and the specialist layer underneath it is open, at a price.
Understanding this reframes the decision. You are not trying to sneak into the cheap tier. You are buying underwriting from someone who has priced your category deliberately and won't reverse the decision when a risk algorithm notices you.
The disclosure rule — read this part twice
Almost every frozen-funds story in this category traces back to the same moment: the merchant application, where the business got described as something softer than it is. "Supplements." "Lab supplies." "Nutraceuticals." "Wellness."
There's a practical argument here as well as an ethical one, and they point the same direction. An underwriter who knows you sell research peptides and approves you anyway cannot later "discover" it. There is nothing to find. That's what you're actually buying.
So: tell them what you sell. Use the words. Let them price it.
What underwriters actually review
Underwriting a high-risk account is largely a review of your website plus your paperwork. Before you apply, assume a human will open your site and read it critically.
Your website
- Product and category pages. Consistent research-use-only framing. No dosing, no administration instructions, no human-use language, no therapeutic or benefit claims — anywhere, including old blog posts.
- Policies that exist and are reachable. Refund, shipping, privacy, and terms, linked from the footer, and matching how you actually operate. A refund policy you don't follow is worse than none.
- Contact reality. A working phone number, a real business address, and support email on your own domain. Free-mail addresses and a contact form alone read as a red flag.
- A finished site. Not a coming-soon page, not lorem ipsum on the about page, not broken product images.
Your paperwork
| Document | Why they want it |
|---|---|
| Registered entity + EIN | Confirms a real business exists and who is behind it |
| Business bank account in the entity's name | Where settlements land; personal accounts get declined |
| 3–6 months of bank statements | Evidence of genuine trading volume and cash flow |
| Prior processing statements | Shows real chargeback ratios rather than projections |
| Government ID for all 25%+ owners | Beneficial-ownership requirements |
| Fulfilment description | Who ships, from where, how fast, what happens on failure |
| Chargeback history and plan | Both the numbers and what you do to keep them down |
Reserves: expect one, negotiate the terms
A reserve is the processor holding back part of your revenue against future chargebacks and refunds. In high-risk approvals, reserves are standard. The useful question is never "how do I avoid a reserve" — it's which structure you get, and for how long.
| Structure | How it works | What moves |
|---|---|---|
| Rolling | A fixed percentage of each settlement batch is held and released on a schedule, commonly 90–180 days. | Both the percentage and the release window, especially after six clean months. |
| Capped | Held until the reserve reaches a ceiling, then it stops growing. | Always ask for a cap. Uncapped rolling reserves scale painfully with growth. |
| Upfront | A lump sum deposited before processing begins. | Sometimes tradeable against a lower rolling percentage. |
Four questions to get answered in writing before you sign:
- What is the exact reserve percentage, and is it capped?
- What is the release schedule, in days?
- What specifically triggers an increase?
- What are the written conditions for reviewing it downward after clean history?
Get these in the agreement, not in an email from a sales rep who won't be there in a year. Rolling reserves for peptide brands goes deeper on the cash-flow modelling.
What it costs
Pricing varies enough by volume, history, and processor that any specific number you read online is close to meaningless. What's reliable is the shape of the pricing:
- A meaningfully higher effective rate than a mainstream aggregator's headline pricing.
- Possible application and setup fees, which reputable processors will explain rather than bury.
- Monthly account and gateway fees.
- Per-chargeback fees, which climb quickly if your ratio drifts.
- A reserve, as above.
Founders instinctively shop on rate. That's the wrong optimisation. A few points of effective rate is a rounding error next to a 180-day hold on your working capital or a MATCH listing that closes the market for five years. Optimise for the approval that holds, then negotiate the rate down once you have clean processing history to point at.
Before you apply: the checklist
Applications get declined for missing paperwork far more often than for the category itself. Work through this first:
- Registered entity, EIN, and a business bank account in the entity's name
- 3–6 months of business bank statements
- Prior processing statements, if any exist
- Government ID and ownership breakdown for every 25%+ owner
- A live, finished website — not a placeholder
- RUO framing audited across every product, category, and blog page
- Refund, shipping, privacy, and terms pages linked in the footer
- Working phone, genuine business address, domain-based support email
- A written description of your fulfilment process
- An honest, prepared answer on any prior termination or MATCH listing
- A chargeback-prevention plan: clear billing descriptor, fast support, tracked shipping, signature confirmation on high-value orders
That last one matters more than founders expect. A recognisable billing descriptor alone prevents a meaningful share of "I don't recognise this charge" disputes, and dispute ratio is the number that decides whether your reserve gets reviewed downward or upward.
The alternative: no checkout at all
A high-risk merchant account isn't the only workable answer. The other is to remove the processor from the storefront entirely.
In an inquiry-based ordering model, there's no public card checkout. Researchers request a quote, you review the account, and you invoice. The public site still has crawlable product, category, and resource pages — so the SEO still works — but there is no processor sitting on your storefront to freeze.
It adds friction and slows the funnel. In exchange, it removes the single largest failure mode in the category. For brands with higher order values, or founders who've already been burned once, it's frequently the better trade.
Most mature operations end up hybrid: an underwritten account for standard orders, an inquiry path for large or unusual volume.
If you've already been terminated
A prior termination is an obstacle, not a wall — but the sequence matters. Preserve your records, find out whether you were reported to MATCH and on which reason code, fix whatever on the storefront triggered the review, and then apply somewhere that underwrites the category with full disclosure of the history.
What doesn't work is submitting the same profile to a second aggregator and hoping. That tends to produce a second termination and a second reason code. The step-by-step is in what to do when a peptide merchant account is terminated.
The takeaway
A high-risk merchant account is the boring, expensive, correct answer for a research-peptide brand that wants public card checkout. It costs more because someone is genuinely pricing your risk instead of ignoring it until it becomes your problem.
The founders who keep processing did three things: they described the business accurately, they built a storefront that survived being read by an underwriter, and they modelled the reserve into their cash flow before it surprised them.
That's what we build and connect founders to — the storefront underwriters approve, the compliance layer underneath it, and the processor relationships on the other side.